Skip to main content
NewslettersWatchlist

Zymeworks Inc(ZYME-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low13.57
Day High14.54
Open:13.74
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
the globe and mail
the globe and mail

Rare milestone for Canadian biotech as Zymeworks-developed drug gets FDA approval

Jazz Pharmaceuticals says the U.S. Food and Drug Administration has approved use of the tumor-fighting antibody to treat adults with a form of biliary-tract cancer (BTC)
GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
GlobeNewswire
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
GlobeNewswire
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors
GlobeNewswire
Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results
GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
GlobeNewswire
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
GlobeNewswire
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
GlobeNewswire
Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024
Newswire.ca
Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players
BayStreet.ca
Recent Breakthroughs in Cancer Research Could Impact These Key Companies
GlobeNewswire
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
GlobeNewswire
Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)
GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
GlobeNewswire
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
GlobeNewswire
Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results
GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
GlobeNewswire
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
GlobeNewswire
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
GlobeNewswire
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
GlobeNewswire
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
GlobeNewswire
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences

Profile

Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.